<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765218</url>
  </required_header>
  <id_info>
    <org_study_id>1182678</org_study_id>
    <nct_id>NCT01765218</nct_id>
  </id_info>
  <brief_title>Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy</brief_title>
  <official_title>Topiramate as an Adjuvant to Therapeutic Hypothermia for Infants With Hypoxic Ischemic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristin R Hoffman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to see whether topiramate (an anti-epileptic agent) improves the outcome of
      babies with neonatal hypoxic encephalopathy who are receiving whole body cooling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic ischemic encephalopathy (HIE) is a devastating and unexpected disease in newborns
      that affects 1.5-2.6 per 1000 live births. Hypoxic ischemic encephalopathy has a mortality
      rate of up to 30% and survivors are at significant risk for adverse long-term outcomes,
      including seizures, cerebral palsy, and developmental delay. The investigators propose a
      randomized controlled study comparing therapeutic hypothermia alone, or therapeutic
      hypothermia combined with topiramate. The investigators hypothesize that adjuvant therapy
      with topiramate will reduce short term severity of HIE including seizures (the primary
      outcome), a composite HIE severity score, and reduce the time of normalization of the
      amplitude integrated EEG (aEEG). The investigators further hypothesize, that it will improve
      longer term outcomes such as developmental outcome. The primary hypothesis is that seizures
      before hospital discharge (or before 4 weeks post-natal age (which ever is earlier)) will be
      significantly reduced in the topiramate group compared to the control group
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizures</measure>
    <time_frame>At 4 weeks post-natal age or the time of hospital discharge (whichever is earlier)</time_frame>
    <description>Clinical or electrical seizures occuring before hospital discharge or before 4w post-natal age (which ever is earlier) will be compared between the topiramate and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIE score</measure>
    <time_frame>At 4 weeks post-natal age or the time of hospital discharge (whichever is earlier)</time_frame>
    <description>Differences in daily HIE score between the two groups will be compared from birth to day-5, and from birth to the time of discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of aEEG</measure>
    <time_frame>At 4 weeks post-natal age or the time of hospital discharge (whichever is earlier)</time_frame>
    <description>The time for normalization of aEEG voltages will be compared in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S100-beta levels</measure>
    <time_frame>Day of life 1, 3 and 7</time_frame>
    <description>Serum and urine S100beta levels (a marker of neuronal injury) will be compared in the two groups at three time points (on day of life 1, 3, and 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI score</measure>
    <time_frame>On day 5-7 of life</time_frame>
    <description>The MRI score on day 5 to 7 of life will be compared in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Outcome</measure>
    <time_frame>At 9, 18 and 27 months</time_frame>
    <description>Bayley scales of infant development III will be compared in the two groups at 9, 18 and 27m of age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
    <other_name>Topiragen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo identical in appearance to the active agent (topiramate)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be eligible for cooling the baby must meet all three of the following sets of
        criteria

          1. Be near term (typically â‰¥34wks gestation) and be aged &lt; 6h old

          2. Have signs of early perinatal depression (EITHER 10 minute Apgar score &lt; 5, OR pH &lt;
             7.00 within 60mins of age, OR Base Excess &lt; -12 within 60mins of age, OR need
             respiratory support at 10min of age due to respiratory depression)

          3. Have signs of moderate or severe encephalopathy based on either clinical examination
             or on amplitude integrated aEEG assessment

        Exclusion Criteria:

          1. Known congenital myopathy

          2. Known congenital neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin R Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin R Hoffman, MD</last_name>
    <phone>916-734-3261</phone>
    <email>krhoffman@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Rottkamp, MD, PhD</last_name>
    <email>carottkamp@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin R Hoffman, MD</last_name>
      <phone>916-734-3261</phone>
      <email>krhoffman@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Rottkamp, MD</last_name>
      <email>carottkamp@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kristin R Hoffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Rottkamp, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameeia Iqbal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Kristin R Hoffman</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Hypoxic ischemic encephalopathy</keyword>
  <keyword>HIE</keyword>
  <keyword>Perinatal depression</keyword>
  <keyword>Whole body cooling</keyword>
  <keyword>Therapeutic hypothermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

